Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
AVIR

AVIR - Atea Pharmaceuticals Inc Stock Price, Fair Value and News

$4.49+0.13 (+2.98%)
Delayed as of 12 Jun 2026, 04:00 pm ET

27/100

AVIR

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

27/100

AVIR

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

AVIR Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

AVIR Price Action

Last 7 days

5.7%

Last 30 days

-1.8%

Last 90 days

-26.4%

Trailing 12 Months

39.9%

AVIR RSI Chart

AVIR Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

AVIR Valuation

Market Cap

359.3M

Price/Earnings (Trailing)

-2.12

Price/Sales (Trailing)

25.63

EV/EBITDA

-1.6

Price/Free Cashflow

-2.43

AVIR Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

AVIR Fundamentals

AVIR Revenue

Revenue (TTM)

14.0M

Rev. Growth (Yr)

-47.35%

Rev. Growth (Qtr)

-20.64%

AVIR Earnings

Earnings (TTM)

-169.5M

Earnings Growth (Yr)

-32.59%

Earnings Growth (Qtr)

-1.28%

AVIR Profitability

EBT Margin

-1253.97%

Return on Equity

-72.53%

Return on Assets

-63.47%

Free Cashflow Yield

-41.15%

AVIR Investor Care

Buy Backs (1Y)

6.49%

Diluted EPS (TTM)

-2.11

AVIR Alerts

  • 1 major insider buys recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202614.0M000
202523.6M21.3M18.8M16.4M
202429.8M29.1M27.5M25.5M
202317.4M23.6M27.1M29.2M
2022266.3M181.3M96.2M11.2M
2021124.3M200.0M275.7M351.4M
202000048.6M
20190000
Get all data in R, Python etc through our Historical Stock Data APIs

About Atea Pharmaceuticals Inc

AVIR
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase III SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, a drug that is in Phase II clinical trial for the treatment and prophylaxis of dengue; and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, and Zika virus, as well as Ruzasvir, an investigational NS5A inhibitor for the treatment of chronic HCV infection. It also develops a co-formulated, oral, pan-genotypic fixed dose combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virous (HCV); It has a license agreement with Merck & Co, Inc. development, manufacture, and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
 CEO
 WEBSITEhttps://ateapharma.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES72

Atea Pharmaceuticals Inc Frequently Asked Questions

AVIR is the stock ticker symbol of Atea Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Jun 12 2026, market cap of Atea Pharmaceuticals Inc is 359.32 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Jun 12 2026, AVIR's PE ratio (Price to Earnings) is -2.12 and Price to Sales (PS) ratio is 25.63. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AVIR PE ratio will change depending on the future growth rate expectations of investors.